Welcome to our dedicated page for Rocket Pharmaceu SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rocket Pharmaceuticals’ 10-K isn’t just numbers—it’s 250+ pages of gene-therapy science, trial protocols and dilution math that can overwhelm even seasoned analysts. If you’re trying to pinpoint when a lentiviral program moves from Phase 1 to Phase 2, trace cash-burn trends, or monitor executive stock sales, traditional SEC readers make the search slow. That complexity is exactly why our AI-powered Stock Titan hub exists.
Every submission—from a Rocket Pharmaceuticals quarterly earnings report 10-Q filing to the next Rocket Pharmaceuticals 8-K material events explained—appears here seconds after hitting EDGAR. Our engine produces plain-English summaries, highlights trial-related risk factors and surfaces critical numbers. Need governance details? The Rocket Pharmaceuticals proxy statement executive compensation section is broken down so you see option grants alongside milestone-based bonuses. Tracking insider sentiment? Receive alerts for Rocket Pharmaceuticals insider trading Form 4 transactions and view Rocket Pharmaceuticals Form 4 insider transactions real-time. Key filing insights include:
- Pipeline spend vs. runway in every Rocket Pharmaceuticals annual report 10-K simplified
- Sequential data on trial enrollment from each 10-Q earnings update
- Cash-raising shelf registrations flagged within S-3 filings
- Director buys and sells via Rocket Pharmaceuticals executive stock transactions Form 4
- Partnership or FDA feedback disclosed through 8-K items
With AI-generated redline comparisons and exportable tables, understanding Rocket Pharmaceuticals SEC documents with AI becomes practical—not a weekend project. Use our concise Rocket Pharmaceuticals earnings report filing analysis to gauge milestone catalysts, or set custom watchlists so you never miss the next data-driven move. Complex biotech filings, clarified and delivered in real time.
Rocket Pharmaceuticals, Inc. (RCKT) – Form 144 filing discloses that insider Aaron Ondrey intends to sell 1,477 common shares through Fidelity Brokerage Services on 07 July 2025. The planned transaction is valued at approximately $4,256.42, based on the market price at the time of filing. The shares were acquired via restricted-stock vesting on 01 July 2025 and constitute less than 0.002% of the 107.7 million shares outstanding. The insider previously sold 7,489 shares on 04 Apr 2025 for $39,646.77.
The filing is a routine notification under Rule 144 and does not, by itself, indicate any change to Rocket Pharmaceuticals’ fundamentals. The modest size of the transaction suggests minimal dilution or ownership impact for existing shareholders.
Rocket Pharmaceuticals, Inc. (RCKT) filed a Form 8-K reporting the results of its 18 June 2025 Annual Meeting.
- Quorum: 91,366,461 shares represented, or approximately 85.56% of outstanding common stock.
- Director elections: All ten nominees were elected. “For” votes ranged from 55.35 M to 78.60 M, with David P. Southwell receiving the highest opposition (23.79 M withheld).
- Auditor ratification: EisnerAmper LLP approved with 90.70 M For, 0.14 M Against, 0.53 M Abstain.
- Say-on-Pay: Executive compensation passed on an advisory basis (77.19 M For, 1.44 M Against, 0.52 M Abstain).
The vote results indicate broad shareholder support for the board, management and governance practices; no other material events were disclosed.
FAQ
What is the current stock price of Rocket Pharmaceu (RCKT)?
What is the market cap of Rocket Pharmaceu (RCKT)?
What is Rocket Pharmaceu's primary focus?
How does Rocket Pharmaceu differentiate itself in the biotechnology industry?
What type of therapies does the company develop?
How important are collaborations to Rocket Pharmaceu’s business model?
What does the company’s research and development strategy focus on?
How does Rocket Pharmaceu address clinical and regulatory challenges?
How is Rocket Pharmaceu positioned within its competitive landscape?
What potential impact does Rocket Pharmaceu have on patient care?
